NIELSEN BioSciences

LOOKING FOR COMMERCIALIZATION PARTNERS FOR DIFFERENTIATED LATE-STAGE ASSET TO DRIVE INNNOVATION IN MEDICAL DERMATOLOGY

- De-risked late-stage asset in Phase III with anticipated filing in 2026 with US FDA and PMDA in Japan
- Opportunity to launch 1st FDA-approved therapeutic in a market with 4.7M annual treatments and no approved therapeutic solution.
- Differentiated product profile with high level of acceptance among Dermatologists, well-researched reimbursement pathway.
- Existing US-based manufacturing along with fully owned IP and multi-decade established safety record
- Exclusive agreement with Maruho Ltd., Japan's largest Dermatology company[1] for the commercialization of CANDIN in Japan
- Actively looking for commercialization partners for CANDIN in the US and other territories

Nielsen BioSciences, Inc. is a privately-held, San Diego-based biopharmaceutical company focused on developing and commercializing biological products with wide-ranging applications in cell-mediated immune responses.

Unmet Medical Need Verruca Vulgaris (common warts) are benign (noncancerous) growths caused by the human papillomavirus (HPV) that can develop on skin and mucosa. Warts have an annual incidence of 1-2% of the population. 50% of patients seek medical treatment. Dermatologists treat ~50% of warts in the US. Current treatment approaches such as cryotherapy, electrosurgery or caustic agents are non-specific in their mechanism of action, relying on local destruction of tissue. Warts are a cutaneous manifestation of human papilloma virus (HPV) infection. A therapy directed at eliminating or controlling the viral infection is thought to be a more effective mechanism of treatment.



Our Solution CANDIN is a purified candida albicans antigen administered by intralesional injection. The use of candida albicans antigen for treatment of warts is well documented, however no placebo-controlled studies were ever conducted. No FDA-approved treatments are available. We believe in the potential of CANDIN to address many HPV-driven diseases beyond the treatment of warts, which provides long-term growth potential.



Regulatory Status Nielsen conducted a successful Phase II program establishing safety, efficacious clearance and fast resolution of warts compared to

standard-of-care. Nielsen is currently conducting a Phase III study to demonstrate safety and efficacy across multiple relevant endpoints. The study is fully enrolled and filing with the US FDA and Japanese PMDA is planned for after completion of the study (currently projected for Q4 2025). Filing with Japanese PMDA will be conducted in collaboration with Maruho Ltd. of Japan.

Commercial Opportunity In 2023, physicians billed for 4.7M treatments for wart destruction and removal. Primary Care and Family Care physicians often refer complex wart cases to Dermatologists making warts are a very common occurrence at the Dermatologist office. We estimate that about 8% of all visits to Dermatologists are for the treatment of warts.



Dermatologists are dissatisfied with existing treatment modalities. This dissatisfaction is characterized by lengthy treatment cycles resulting in a high number of visits, pain and discomfort along with cosmetic concerns. Market research conducted by Nielsen in 2024 confirms a high degree of acceptance of the clinical profile of CANDIN as well as associated practice economics.

We believe in the potential of CANDIN to provide a significant improvement to standard-of-care aiming at efficacy, faster resolution of warts and a patient-preferred less painful treatment modality.

Operational Expertise & Intellectual Property CANDIN is manufactured in San Diego, CA. CANDIN can rely on a decade long safety record with more than 9 million doses used as a recall antigen for determining presence of anergy. CANDIN provides a highly differentiated product profile as the only purified candida albicans antigen. It follows strict manufacturing standards for purity and consistency and has been the focus of multiple clinical studies to demonstrate its effectiveness as immunotherapy. CANDIN Intellectual property is strong and secured long-term through several patents in the US and globally.

Collaboration Opportunities Nielsen BioSciences is looking for partners with existing commercial infrastructure to commercialize CANDIN and provide a valuable addition to the treatment armamentarium in the US and other countries. Nielsen already entered into an Agreement with Maruho Co. Ltd to for exclusive commercialization of CANDIN in Japan. Nielsen is actively looking for commercialization partners for CANDIN in the US and other territories.

NIELSEN BioSciences
Christoph Wulf
Vice President, Head of Commercial

Nielsen BioSciences, Inc.
11125 Flintkote Ave, Suite G
San Diego, CA 92121
(617) 999 5892
christoph@nielsenbio.com